Literature DB >> 21160069

Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes.

Xingmin Feng1, Phillip Scheinberg, Colin O Wu, Leigh Samsel, Olga Nunez, Courtney Prince, Rebecca D Ganetzky, J Philip McCoy, Jaroslaw P Maciejewski, Neal S Young.   

Abstract

Although aplastic anemia and myelodysplasia have been extensively investigated, little is known about their circulating cytokine patterns. We compared plasma soluble cytokines in 33 aplastic anemia, 57 myelodysplasia patients, and 48 healthy controls. High levels of thrombopoietin and granulocyte colony-stimulating factor, with low levels of CD40 ligand, chemokine (C-X-C motif) ligand 5, chemokine (C-C motif) ligand 5, chemokine (C-X-C motif) ligand 11, epidermal growth factor, vascular endothelial growth factor, and chemokine (C-C motif) ligand 11 were a signature profile for aplastic anemia. High levels of tumor necrosis factor-α, interleukin-6, chemokine (C-C motif) ligand 3, interleukin-1 receptor antagonist, and hepatocyte growth factor were a cytokine signature for myelodysplasia. Despite similar clinical presentations, distinct cytokine profiles were observed between aplastic anemia and hypocellular myelodysplasia. Future studies focusing on cytokines that better discriminate these two entities such as thrombopoietin and chemokine (C-C motif) ligand 3 may be useful tools in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21160069      PMCID: PMC3069238          DOI: 10.3324/haematol.2010.030536

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  16 in total

1.  Tumor necrosis factor-alpha and tumor necrosis factor-beta (lymphotoxin) stimulate the production of granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and IL-1 in vivo.

Authors:  K Kaushansky; V C Broudy; J M Harlan; J W Adamson
Journal:  J Immunol       Date:  1988-11-15       Impact factor: 5.422

Review 2.  Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology?

Authors:  J Barrett; Y Saunthararajah; J Molldrem
Journal:  Semin Hematol       Date:  2000-01       Impact factor: 3.851

3.  Serum thrombopoietin levels in patients with aplastic anaemia.

Authors:  J C Marsh; F M Gibson; R L Prue; A Bowen; V T Dunn; A C Hornkohl; J L Nichol; E C Gordon-Smith
Journal:  Br J Haematol       Date:  1996-12       Impact factor: 6.998

Review 4.  The World Health Organization (WHO) classification of the myeloid neoplasms.

Authors:  James W Vardiman; Nancy Lee Harris; Richard D Brunning
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

5.  Stem cell factor production by human marrow stromal fibroblasts.

Authors:  M L Linenberger; F W Jacobson; L G Bennett; V C Broudy; F H Martin; J L Abkowitz
Journal:  Exp Hematol       Date:  1995-09       Impact factor: 3.084

6.  Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia.

Authors:  S J Rosenfeld; J Kimball; D Vining; N S Young
Journal:  Blood       Date:  1995-06-01       Impact factor: 22.113

7.  Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine.

Authors:  Phillip Scheinberg; Colin O Wu; Olga Nunez; Neal S Young
Journal:  J Pediatr       Date:  2008-07-30       Impact factor: 4.406

8.  Transcriptional regulation of the human MIP-1alpha promoter by RUNX1 and MOZ.

Authors:  Claire A P Bristow; Paul Shore
Journal:  Nucleic Acids Res       Date:  2003-06-01       Impact factor: 16.971

9.  Regulation of erythropoietin and burst-promoting activity production in patients with aplastic anemia and iron deficiency anemia.

Authors:  N Takeichi; T Umemura; J Nishimura; S Motomura; M Kozuru; H Ibayashi
Journal:  Acta Haematol       Date:  1988       Impact factor: 2.195

10.  Measurement of endogenous plasma granulocyte colony-stimulating factor in patients with acquired aplastic anemia by a sensitive chemiluminescent immunoassay.

Authors:  S Kojima; T Matsuyama; Y Kodera; H Nishihira; K Ueda; T Shimbo; T Nakahata
Journal:  Blood       Date:  1996-02-15       Impact factor: 22.113

View more
  46 in total

1.  Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ.

Authors:  Luigi J Alvarado; Heather D Huntsman; Hai Cheng; Danielle M Townsley; Thomas Winkler; Xingmin Feng; Cynthia E Dunbar; Neal S Young; Andre Larochelle
Journal:  Blood       Date:  2019-02-25       Impact factor: 22.113

Review 2.  The bone-marrow niche in MDS and MGUS: implications for AML and MM.

Authors:  Irene M Ghobrial; Alexandre Detappe; Kenneth C Anderson; David P Steensma
Journal:  Nat Rev Clin Oncol       Date:  2018-01-09       Impact factor: 66.675

3.  Decreased plasma cytokines are associated with low platelet counts in aplastic anemia and immune thrombocytopenic purpura.

Authors:  X Feng; P Scheinberg; L Samsel; O Rios; J Chen; J P McCoy; W Ghanima; J B Bussel; N S Young
Journal:  J Thromb Haemost       Date:  2012-08       Impact factor: 5.824

4.  Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug.

Authors:  Ronan Desmond; Danielle M Townsley; Bogdan Dumitriu; Matthew J Olnes; Phillip Scheinberg; Margaret Bevans; Ankur R Parikh; Kinneret Broder; Katherine R Calvo; Colin O Wu; Neal S Young; Cynthia E Dunbar
Journal:  Blood       Date:  2013-12-17       Impact factor: 22.113

Review 5.  Activity of eltrombopag in severe aplastic anemia.

Authors:  Phillip Scheinberg
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 6.  Nontransplant therapy for bone marrow failure.

Authors:  Danielle M Townsley; Thomas Winkler
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 7.  Activity of eltrombopag in severe aplastic anemia.

Authors:  Phillip Scheinberg
Journal:  Blood Adv       Date:  2018-11-13

8.  Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.

Authors:  Danielle M Townsley; Phillip Scheinberg; Thomas Winkler; Ronan Desmond; Bogdan Dumitriu; Olga Rios; Barbara Weinstein; Janet Valdez; Jennifer Lotter; Xingmin Feng; Marie Desierto; Harshraj Leuva; Margaret Bevans; Colin Wu; Andre Larochelle; Katherine R Calvo; Cynthia E Dunbar; Neal S Young
Journal:  N Engl J Med       Date:  2017-04-20       Impact factor: 91.245

Review 9.  Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes.

Authors:  I Gañán-Gómez; Y Wei; D T Starczynowski; S Colla; H Yang; M Cabrero-Calvo; Z S Bohannan; A Verma; U Steidl; G Garcia-Manero
Journal:  Leukemia       Date:  2015-03-12       Impact factor: 11.528

Review 10.  Border between aplastic anemia and myelodysplastic syndrome.

Authors:  Hirohito Yamazaki; Shinji Nakao
Journal:  Int J Hematol       Date:  2013-04-24       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.